Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

This study is testing a combination of three drugs — a liposomal form of mitoxantrone, cytarabine, and venetoclax — in people with relapsed or refractory acute myeloid leukemia (AML), a blood cancer that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with AML (excluding acute promyelocytic leukemia) that has relapsed or is refractory, meaning: standard initial treatment failed after 2 cycles, your leukemia returned after a remission, or your minimal residual disease (MRD) went from undetectable to detectable again - Your general health score (ECOG) is 0–2 - Your organ function is adequate for treatment **You may NOT be eligible if...** - You have acute promyelocytic leukemia (a specific AML subtype treated differently) - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding - You have active serious infections or other major health conditions Talk to your doctor to see if this trial is right for you.